JG
AIMT

Jefferies Group’s Aimmune Therapeutics AIMT Stock Holding History

Jefferies Group’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-14,943
Closed -$313K – 3220
2019
Q3 		$313K Buy
14,943
+8,692
+139% +$177K ﹤0.01% 2160
2019
Q2 		$130K Buy
+6,251
New +$129K ﹤0.01% 2240
2018
Q4 		– Sell
-1,706
Closed -$47K – 2768
2018
Q3 		$47K Sell
1,706
-7,593
-82% -$215K ﹤0.01% 2279
2018
Q2 		$250K Buy
9,299
+7,000
+304% +$214K ﹤0.01% 1933
2018
Q1 		$73K Buy
+2,299
New +$80.9K ﹤0.01% 2100

Other funds holding AIMT

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Jefferies Group's AIMT Position: Q4 2019 in Review

Jefferies Group sold out of Aimmune Therapeutics (AIMT) in Q4 2019, closing a stake of 14,943 shares — an estimated $313K sold.

Jefferies Group first reported a position in AIMT in Q1 2018 and held it in 5 quarters. The position peaked at $313K in Q3 2019. 155 funds tracked by Wall St. Rank hold AIMT as of Q4 2019.

  • Jefferies Group reported no remaining Aimmune Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Jefferies Group sold 14,943 Aimmune Therapeutics shares in Q4 2019, an estimated $313K.
  • Jefferies Group first reported a position in Aimmune Therapeutics in Q1 2018 and held it in 5 quarters.
  • Jefferies Group's Aimmune Therapeutics position peaked at $313K in Q3 2019.
  • 155 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2019.

Based on Jefferies Group's 13F filing for Q4 2019, filed 13 Feb 2020.